Coloplast A/S - Full-Year Financial Results 2024/25

Core Insights - Coloplast reported a Q4 organic growth of 7% and an EBIT margin of 28%, with reported revenue in DKK remaining flat due to currency impacts and the divestment of the Skin Care segment [1][6] Business Area Performance - Ostomy Care: Achieved 7% organic growth, driven by product launches, particularly in Europe and Emerging Markets, while sales in China declined due to negative consumer sentiment and competitive pressures [2] - Continence Care: Growth of 9% was supported by strong sales of the Luja™ product for both male and female users [2] - Voice & Respiratory Care: Experienced 9% growth, attributed to strong performance in Laryngectomy and Tracheostomy segments [2] - Wound & Tissue Repair: Kerecis grew by 20% with a 14% EBIT margin before PPA amortization; however, Advanced Wound Dressings saw a decline of 6% due to a product return in China, impacting revenue by approximately DKK 60 million [3] - Interventional Urology: Growth was driven by the US Men's Health business, partially offset by a product recall in Kidney & Bladder Health, which negatively impacted revenue by around DKK 15 million in Q4 [4] Financial Performance - EBIT for the year was DKK 7,670 million, reflecting a 5% increase from the previous year, with an EBIT margin of 28%, up from 27% [11] - Adjusted net profit before special items was DKK 5,148 million, a DKK 123 million increase year-over-year, with adjusted diluted EPS before special items rising by 2% to DKK 22.84 [11] - The Board of Directors recommended a year-end dividend of DKK 18.00 per share, totaling DKK 23.00 for the year, compared to DKK 22.00 last year [7] Future Guidance - For FY 2025/26, the company anticipates around 7% organic revenue growth and EBIT growth in constant currencies, with reported growth in DKK expected at 4-5% [8] - The guidance assumes continued strong performance in Chronic Care and improved momentum in Acute Care, with a negative impact from currencies and the Skin Care divestment [8] - EBIT growth in constant currencies is expected to be supported by stable inflation levels and new investments related to the Impact4 strategy [9]